Aquestive Therapeutics plans to resubmit its Anaphylm application to the FDA in Q3 2026 with over $150M in cash projected at launch. Aquestive Therapeutics announced plans to resubmit its Anaphylm application to the FDA in the third quarter of 2026. The company projects it
Cisco Systems (NASDAQ: CSCO) reported fiscal Q3 2026 earnings last night. Investors loved what they saw, and the stock is up by 17% at 10 a.m ET. Cisco crushed expectations This was a clean beat-and-raise report. Cisco's Q3 sales rose 12% year over year to $15.8 bil
Quick Read - Mizuho analyst raised Affirm’s (AFRM) price target to $100 from $95 on credibility of disclosed $100B GMV target implying ~25% annual growth. - Affirm’s execution momentum and diversification into the Affirm Card business is outpacing competitors like Klarna (KLAR)...</strong
The semiconductor firm reported no revenue and a deeper net loss but highlighted a growing $300 million sales opportunity funnel. Ideal Power reported a net loss of $3.6 million for Q1, widening from the prior period, with no revenue generated. Cash burn totaled $2.3 milli
The LiDAR firm maintained its full-year revenue guidance of $67 million to $73 million despite delayed NRE revenue. Innoviz Technologies reported first-quarter revenue of $7.1 million and reaffirmed its 2026 revenue outlook of $67 million to $73 million. The company attrib
The company secured a regulatory win and expanded its commercial pipeline to 7.8 GW amid rising AI and electrification demand. Terrestrial Energy (NASDAQ:IMSR) reported progress in engineering, regulatory, and supply chain efforts during Q1 2026, citing AI data centers, ma
Key Points - AxoGen says its core strategy remains focused on developing the peripheral nerve repair market, and CEO Michael Dale reiterated confidence in the company’s Avance platform as a differentiated solution. - Recent reimbursement wins and the CMS outpatient rate increase...</stron
Key Points - Fermi’s board and leadership were overhauled after former CEO Toby Neugebauer was removed “for cause,” with the company expanding its board and launching a CEO search as it shifts into what management calls “Fermi 2.0.” - Management says commercial momentum is...
Key Points - Fennec Pharmaceuticals reported strong Q1 2026 results, with net product sales rising about 73% year over year to $15.1 million and positive operating cash flow. Management said it was the sixth straight quarter of sales growth. - The company’s expanded sales
Key Points - DeFi Development reiterated that its core mission is to provide leveraged exposure to Solana, with management saying success is measured primarily by SOL per share. The company said its strategy includes validators, partnerships, treasury deployment and ecosys
ادخل بحساب جوجل لمشاركة رأيك والتفاعل مع الأخبار — بلا كلمة مرور.
إيميلك يبقى موثّقاً وخصوصيتك محفوظة.